Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SHE:002675)
China · Delayed Price · Currency is CNY 14.25
-0.19 (-1.32%)
Apr 8, 2026, 3:04 PM CST
SHE:002675 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,713 | 2,846 | 3,267 | 3,565 | 3,897 |
Other Revenue | 28.05 | 23.35 | 8.24 | 18.34 | 15.02 |
| 2,741 | 2,869 | 3,276 | 3,583 | 3,912 | |
Revenue Growth (YoY) | -4.46% | -12.42% | -8.58% | -8.41% | 14.42% |
Cost of Revenue | 1,356 | 1,521 | 1,922 | 2,051 | 2,324 |
Gross Profit | 1,385 | 1,348 | 1,354 | 1,532 | 1,588 |
Selling, General & Admin | 745.12 | 724.93 | 754.41 | 785.29 | 802.41 |
Research & Development | 232.61 | 291.91 | 197.22 | 163.52 | 137.56 |
Other Operating Expenses | 40.71 | 31.76 | 33.87 | 29.19 | 33.34 |
Operating Expenses | 1,033 | 1,065 | 980.31 | 980.56 | 974.77 |
Operating Income | 352.17 | 282.61 | 373.77 | 551.72 | 612.99 |
Interest Expense | -137.54 | -96.51 | -56.76 | -58.64 | -56.45 |
Interest & Investment Income | 5.17 | 5.56 | 12.78 | 13.2 | 5.12 |
Currency Exchange Gain (Loss) | -13.23 | 15.44 | 15.25 | 42.65 | -4.08 |
Other Non Operating Income (Expenses) | -2.23 | -2.79 | -1.17 | -5.94 | -2.58 |
EBT Excluding Unusual Items | 204.34 | 204.31 | 343.86 | 542.97 | 555 |
Impairment of Goodwill | - | -52.6 | - | -80.1 | -211.26 |
Gain (Loss) on Sale of Investments | -15.88 | -12.92 | -28.13 | -39.21 | -12.15 |
Gain (Loss) on Sale of Assets | -0.33 | 0.21 | -0.23 | -0.38 | -0.15 |
Asset Writedown | - | -33.21 | - | - | -0.16 |
Other Unusual Items | 23.3 | 113.31 | 21.77 | 22.3 | 24.82 |
Pretax Income | 211.44 | 219.1 | 337.28 | 445.58 | 356.1 |
Income Tax Expense | 57 | 77.68 | 83.07 | 92.75 | 95.25 |
Earnings From Continuing Operations | 154.44 | 141.43 | 254.22 | 352.83 | 260.85 |
Minority Interest in Earnings | 41.19 | 42.4 | -44.48 | -45.54 | -109.29 |
Net Income | 195.63 | 183.83 | 209.74 | 307.29 | 151.56 |
Net Income to Common | 195.63 | 183.83 | 209.74 | 307.29 | 151.56 |
Net Income Growth | 6.42% | -12.35% | -31.75% | 102.75% | -63.72% |
Shares Outstanding (Basic) | 825 | 825 | 825 | 808 | 802 |
Shares Outstanding (Diluted) | 825 | 825 | 825 | 808 | 802 |
Shares Change (YoY) | 0.01% | -0.01% | 2.10% | 0.68% | 0.01% |
EPS (Basic) | 0.24 | 0.22 | 0.25 | 0.38 | 0.19 |
EPS (Diluted) | 0.24 | 0.22 | 0.25 | 0.38 | 0.19 |
EPS Growth | 6.42% | -12.35% | -33.15% | 101.38% | -63.73% |
Free Cash Flow | 219.03 | -168.94 | -235 | 606.93 | 413.42 |
Free Cash Flow Per Share | 0.27 | -0.20 | -0.28 | 0.75 | 0.52 |
Dividend Per Share | 0.080 | 0.080 | 0.125 | 0.150 | 0.150 |
Dividend Growth | - | -36.00% | -16.67% | - | -40.00% |
Gross Margin | 50.52% | 46.97% | 41.34% | 42.77% | 40.59% |
Operating Margin | 12.85% | 9.85% | 11.41% | 15.40% | 15.67% |
Profit Margin | 7.14% | 6.41% | 6.40% | 8.58% | 3.87% |
Free Cash Flow Margin | 7.99% | -5.89% | -7.17% | 16.94% | 10.57% |
EBITDA | 530.64 | 436.95 | 511.69 | 672.09 | 727.92 |
EBITDA Margin | 19.36% | 15.23% | 15.62% | 18.76% | 18.61% |
D&A For EBITDA | 178.47 | 154.34 | 137.92 | 120.37 | 114.93 |
EBIT | 352.17 | 282.61 | 373.77 | 551.72 | 612.99 |
EBIT Margin | 12.85% | 9.85% | 11.41% | 15.40% | 15.67% |
Effective Tax Rate | 26.96% | 35.45% | 24.63% | 20.82% | 26.75% |
Revenue as Reported | 2,741 | 2,869 | 3,276 | 3,583 | 3,912 |
Advertising Expenses | 0.42 | 0.5 | 1.06 | 0.83 | 0.29 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.